Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joseph G. Oliveto M.B.A. | CEO, President & Director | 949.47k | -- | 1968 |
| Mr. Amit Hasija | CFO & Executive VP of Corporate Development | 634.89k | -- | 1973 |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer | 691.43k | -- | 1962 |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board | -- | -- | 1962 |
| Mr. Jeffrey Nelson | Chief Operating Officer | -- | -- | 1981 |
| Ms. Kim Fox | Vice President of Communications | -- | -- | -- |
| Mr. Roshan Girglani | Vice President of Marketing | -- | -- | -- |
| Mr. Jeff Moore | Vice President of Sales | -- | -- | -- |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board | -- | -- | 1956 |
| Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management | -- | -- | -- |
Milestone Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 33
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 16, 2025 at 12:30 PM UTC
Milestone Pharmaceuticals Inc. Earnings Date
Recent Events
November 20, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission